Australia's Imricor Medical Systems soars on US FDA clearance for MRI catheter
12/01/2026 24:05
** Shares of Australia's Imricor Medical Systems IMR.AX rise as much as 26% to A$1.99, their highest level since July 21, 2021 ** Stock posts its biggest intraday pct gain in nearly three years ** Medical device developer says the U.S. Food and Drug Administration (FDA) has granted clearance to commercially market its Vision-MR Diagnostic Catheter ** Vision-MR Diagnostic Catheter enables electrophysiologists to use MRI for precise, clear visualisation of cardiac anatomy ** IMR rose 12.5% in 2025 (Reporting by Aamir Sheik Khalid in Bengaluru) ((Aamir.SheikKhalid@thomsonreuters.com))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion